IL315059A - Ion channels that open using ligands and methods of using them - Google Patents

Ion channels that open using ligands and methods of using them

Info

Publication number
IL315059A
IL315059A IL315059A IL31505924A IL315059A IL 315059 A IL315059 A IL 315059A IL 315059 A IL315059 A IL 315059A IL 31505924 A IL31505924 A IL 31505924A IL 315059 A IL315059 A IL 315059A
Authority
IL
Israel
Prior art keywords
methods
ion channels
gated ion
ligand gated
ligand
Prior art date
Application number
IL315059A
Other languages
English (en)
Hebrew (he)
Inventor
Anthony Lau
Orion P Keifer Jr
Stefanie Makinson
Corey J Cain
Alexander Naka
Original Assignee
Trames Bio Inc
Anthony Lau
Orion P Keifer Jr
Stefanie Makinson
Corey J Cain
Alexander Naka
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trames Bio Inc, Anthony Lau, Orion P Keifer Jr, Stefanie Makinson, Corey J Cain, Alexander Naka filed Critical Trames Bio Inc
Publication of IL315059A publication Critical patent/IL315059A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/04—Fusion polypeptide containing a localisation/targetting motif containing an ER retention signal such as a C-terminal HDEL motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2842—Pain, e.g. neuropathic pain, psychogenic pain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL315059A 2022-02-18 2023-02-21 Ion channels that open using ligands and methods of using them IL315059A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263311735P 2022-02-18 2022-02-18
US202263348560P 2022-06-03 2022-06-03
PCT/US2023/062943 WO2023159247A1 (en) 2022-02-18 2023-02-21 Ligand gated ion channels and methods of use

Publications (1)

Publication Number Publication Date
IL315059A true IL315059A (en) 2024-10-01

Family

ID=87579027

Family Applications (1)

Application Number Title Priority Date Filing Date
IL315059A IL315059A (en) 2022-02-18 2023-02-21 Ion channels that open using ligands and methods of using them

Country Status (10)

Country Link
US (1) US20250163130A1 (cg-RX-API-DMAC7.html)
EP (1) EP4479421A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025508427A (cg-RX-API-DMAC7.html)
KR (1) KR20240161957A (cg-RX-API-DMAC7.html)
CN (1) CN119137143A (cg-RX-API-DMAC7.html)
AU (1) AU2023221946A1 (cg-RX-API-DMAC7.html)
CA (1) CA3252386A1 (cg-RX-API-DMAC7.html)
IL (1) IL315059A (cg-RX-API-DMAC7.html)
MX (1) MX2024010075A (cg-RX-API-DMAC7.html)
WO (1) WO2023159247A1 (cg-RX-API-DMAC7.html)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6693172B1 (en) * 1999-05-27 2004-02-17 Pharmacia And Upjohn Company Double mutant alpha-7 nicotinic acetylcholine receptor
IL311984A (en) * 2016-07-07 2024-06-01 Hughes Howard Med Inst Modified ligand-gated ion channels and methods of use
IL274702B2 (en) * 2017-11-27 2026-04-01 Coda Biotherapeutics Inc Compounds and methods for neurological diseases
JP7781052B2 (ja) * 2019-08-21 2025-12-05 トレイムス バイオ, インコーポレイテッド 神経学的疾患のための組成物および方法

Also Published As

Publication number Publication date
EP4479421A4 (en) 2026-02-25
KR20240161957A (ko) 2024-11-13
AU2023221946A1 (en) 2024-09-12
JP2025508427A (ja) 2025-03-26
EP4479421A1 (en) 2024-12-25
WO2023159247A1 (en) 2023-08-24
MX2024010075A (es) 2024-11-08
US20250163130A1 (en) 2025-05-22
CA3252386A1 (en) 2023-08-24
CN119137143A (zh) 2024-12-13

Similar Documents

Publication Publication Date Title
GB2591931B (en) Systems and methods for privacy preserving determination of intersections of sets of user identifiers
EP3906061A4 (en) METHODS OF TREATMENT OF CANCER USING COMBINATIONS OF PARP INHIBITORS AND ANTIBODY RADIOCONJUGATE
EP3481858A4 (en) MODIFIED LIGAND-CONTROLLED ION CHANNELS AND METHOD FOR USE THEREOF
IL314320A (en) Compounds and methods of use
ZA201901729B (en) Boron-containing low-carbon steel oxide film and preparation method thereof
MX2024002860A (es) Cierres de tapon y bases para los mismos.
IL310096A (en) CD38 modulators and methods of using them
AU2021376500A9 (en) Application of isoquinoline compound in tumor treatment
HUP2400200A1 (hu) Átalakított kristályformájú prekurzor és annak elõállítási eljárása
GB2628311B (en) Analysis and debugging of fully-homomorphic encryption
IL318209A (en) Medical compounds and methods
EP4041282A4 (en) METHODS OF USE OF IL-33 PROTEIN IN THE TREATMENT OF CANCER
GB2619448B8 (en) Zinc-europium-phosphorus porphyrin cluster material and preparation method and use thereof
IL287117A (en) Compositions and methods of using seneca valley virus (svv) for treating cancer
IL318393A (en) Azaquinazoline compounds and methods of use
EP4161523A4 (en) BICYCLIC HETEROARENES AND METHODS OF USE THEREOF
HK40121744A (en) Ligand gated ion channels and methods of use
IL309878A (en) Therapeutic compounds and methods
EP3752822A4 (en) ION MOBILITY SPECTROMETERS AND METHOD OF ANALYSIS OF IONS
IL314277A (en) Anti-B7-H3 compounds and methods of use
CA3265673A1 (en) Brain-penetrating peptides and their methods of use
IL314368A (en) Therapeutic cytokines and methods
SG10202007214TA (en) Manifold assembly and method of use
GB201913639D0 (en) Kit and method of using kit
GB202218826D0 (en) Assistance apparatuses and methods